Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Managed Healthcare Leads XLV Bounce
When the trend is up, I am generally looking for corrections and trying to find an ETF or stock that has a good chance of hitting a new high. The HealthCare SPDR (XLV) has been one of the strongest SPDRs this year and remains in an uptrend. The chart below shows XLV getting a bounce off support from the June-July lows. It would not take much to push this one to new highs again. The second chart shows the HealthCare Providers ETF (IHF) hitting a 52-week high in late June and then correcting into late July. The ETF broke above the wedge trend line in early August, fell back to test the last July low and surged back above 140 this week. The breakout remains valid and bullish.
JLS Monday, 08/17/15 06:33:07 PM
Re: TREND1 post# 14048
Post # of 14052
Do you know ...
Drugs applied directly to the skin bypass the liver.
http://tinyurl.com/nu4364o
http://tinyurl.com/pt62mef
What about Omnipod? It's a type of patch, and a lot more -- it has brains.
http://tinyurl.com/og23fh4
And last but not least ...
As for huge breakthroughs ... Diabetics could soon produce their own insulin. Maybe this is why A. Man is not in such a hurry to put more money into MannKind.
http://tinyurl.com/o44c24v Just a little teaser below:
In a study published in the journal Cell, a team of Harvard Researchers transformed stem cells - which have the potential to develop into a range of different cell types - into beta cells, which produce insulin to help regulate blood sugar. These cells were then inserted into diabetic mice, whose blood sugar was observed over a few months.
Results showed that the manipulated cells functioned as normal beta cells and were not attacked by the immune system, which is what usually happens in diabetics. The cells had a noticeably fine-tuned response to sugar levels in the blood, and six months later, the mice’s blood sugar remained under control. This is a huge breakthrough that could help free diabetics from daily insulin injections.
Okay kids, I gotta go do some work. Just make sure you do your due diligence and don't put too much money in the wrong place (or in just one place).
JLS Monday, 08/17/15 04:14:40 PM
Re: TREND1 post# 14045
Post # of 14048
Can you say Flozins?
New diabetes drugs -- bypass liver
Been researching that.
"The Arrival of the SGLT2 “Flozins”
Sodium glucose co-transporter-2 (SGLT2) inhibitors are different from most type 2 drugs. Rather than increase insulin production or decrease glucose production, SGLT2s bypass the liver and pancreas and work on the kidneys. In short, the drugs reduce the reabsorption of glucose from the kidneys by making them shunt the glucose into the urinary tract.
The beneficial effects of doing so include negligible risk of hypoglycemia, weight loss, and reduced A1c.
SGLT2 drugs, sometimes referred to as “flozins” because of the last syllables in their name, include canagliflozin (“Invokana,” Johnson & Johnson), dapagliflozin (AstraZeneca and Bristol-Myers Squibb), and empagliflozin (Boehringer Ingelheim and Eli Lilly and Company)."
http://tinyurl.com/py26447
An exhaustive look at diabetes drugs in the pipeline is available at http://tinyurl.com/o626fq2
The PDF, aimed at professionals, is heavy on scientific and medical terminology, but offers useful information to the lay reader.
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
71
|
Created
|
08/18/15
|
Type
|
Premium
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |